ovarian cancer

FDA says Clovis’ Rubraca could be prostate cancer breakthrough

https://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/

Chinese pharma market primed for growth after sweeping reforms

https://pharmaphorum.com/r-d/views-analysis-r-d/chinese-pharma-market/

J&J hopes to overturn $4.69bn compensation bill

https://pharmaphorum.com/news/jj-hopes-to-overturn-4-69bn-compensation-bill/

AstraZeneca/Merck hope for expanded ovarian cancer drug use

https://pharmaphorum.com/news/astrazeneca-mercks-hope-for-expanded-lynparza/

ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combo

https://pharmaphorum.com/views-and-analysis/asco-2018-tesaro-checkpoint-combo/

Clovis’ PARP drug gets new US ovarian cancer use

https://pharmaphorum.com/news/clovis-parp-drug-gets-new-us-ovarian-cancer-use/

Clovis’ Rubraca close to EU approval in ovarian cancer

https://pharmaphorum.com/oncology/clovis-rubraca-close-eu-approval-ovarian-cancer/

AZ’s cancer and respiratory drugs approved in Japan

https://pharmaphorum.com/news/azs-cancer-respiratory-drugs-approved-japan/

AZ’s Lynparza becomes first PARP drug approved in breast cancer

https://pharmaphorum.com/news/azs-lynparza-becomes-first-approved-parp-drug-breast-cancer/

1 2 3

Close in 10 seconds

Pharmaphorum.com

Search